Intensive Care Department, Epworth HealthCare, Epworth Richmond, Victoria, 3121, Australia.
Research Development and Governance, Epworth HealthCare, Richmond, Victoria, 3121, Australia; Department of Health Sciences and Biostatistics, Swinburne University of Technology, Hawthorn, Victoria, 3122, Australia.
Aust Crit Care. 2023 Sep;36(5):787-792. doi: 10.1016/j.aucc.2022.08.012. Epub 2022 Oct 14.
The objective of this study was to evaluate the adequacy of the user seal check (USC) in predicting N95 respirator fit.
This was a prospective, observational study conducted from May to September 2020.
The study setting included three private intensive care units (ICUs) in Victoria, Australia.
ICU staff members in three private ICUs in Melbourne and regional Victoria participated in this study.
The main outcome measure is the proportion of participants who passed a USC and subsequently failed fit testing of an N95 respirator.
Three different respirators were available: two N95 respirator brands and CleanSpace HALO® powered air-purifying respirator. Participants were sequentially tested on N95 respirators followed by powered air-purifying respirators until either successful fit testing or failure of all three respirators. The first N95 tested was based on the availability on the day of testing. The primary outcome was failure rate of fit testing on the first N95 respirator type passing a USC.
Of 189 participants, 22 failed USC on both respirators, leaving 167 available for the primary outcome. Fifty-one of 167 (30.5%, 95% confidence interval = 23.7-38.1) failed fit testing on the first respirator type used that had passed a USC.
USC alone was inadequate in assessing N95 respirator fit and failed to detect inadequate fit in 30% of participants. Mandatory fit testing is essential to ensure adequate respiratory protection against COVID-19 and other airborne pathogens.
Australian New Zealand Clinical Trials Registry: ACTRN12620001193965.
本研究旨在评估使用者密封检查(USC)在预测 N95 呼吸器贴合度方面的充分性。
这是一项于 2020 年 5 月至 9 月进行的前瞻性观察性研究。
该研究地点包括澳大利亚维多利亚州的三个私立重症监护病房(ICU)。
墨尔本和维多利亚地区三个私立 ICU 的 ICU 工作人员参与了这项研究。
主要观察指标是通过 USC 并随后未能通过 N95 呼吸器 fit 测试的参与者比例。
有三种不同的呼吸器可供选择:两种 N95 呼吸器品牌和 CleanSpace HALO®动力空气净化呼吸器。参与者依次接受 N95 呼吸器测试,然后是动力空气净化呼吸器,直到所有三种呼吸器都成功 fit 测试或失败。首先测试的是当天可用的 N95 呼吸器。主要结果是通过 USC 的第一种 N95 呼吸器类型 fit 测试失败率。
在 189 名参与者中,有 22 名在两种呼吸器上均未能通过 USC,因此有 167 名参与者可用于主要结果。在首次使用通过 USC 的呼吸器类型中,有 51 名(167 名中的 30.5%,95%置信区间=23.7-38.1)fit 测试失败。
单独的 USC 不足以评估 N95 呼吸器的贴合度,有 30%的参与者未能检测到贴合度不足。强制性 fit 测试对于确保针对 COVID-19 和其他空气传播病原体的充分呼吸保护至关重要。
澳大利亚新西兰临床试验注册处:ACTRN12620001193965。